PLG and cancer: One potential blood marker for rHGP is SERPINF2 (alpha-2-antiplasmin), which inhibit plasmin and is associated with poor outcome in various cancer due to its role in preventing L1CAM destruction and promoting metastatic outgrowth during brain metastasis [35].